Trial Profile
A Single Dose, Open-Label, Randomized Two-Period Crossover Study in Healthy Young Subjects to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Jul 2016
Price :
$35
*
At a glance
- Drugs Tasimelteon (Primary) ; Tasimelteon (Primary)
- Indications Circadian rhythm sleep disorders
- Focus Pharmacokinetics
- Sponsors Vanda Pharmaceuticals
- 28 Jul 2014 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 08 May 2014 New trial record